Asian Pacific Journal of Cancer Prevention

  • 제16권13호
  • /
  • Pages.5289-5296
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Individualized Chemotherapy for Metastatic Gastric Cancer: Retrospective Data from a University Hospital in Brazil

  • Aguiar, Pedro Nazareth Junior (Oncology Division, Department of Oncology and Hematology, Federal University of Sao Paulo - Escola Paulista de Medicina) ;
  • Ribas, Christian (Oncology Division, Department of Oncology and Hematology, Federal University of Sao Paulo - Escola Paulista de Medicina) ;
  • Forones, Nora Manoukian (Oncology Group, Gastroenterology Division, Department of Medicine Federal University of Sao Paulo - Escola Paulista de Medicina)
  • 발행 : 2015.08.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Despite the decreased incidence, gastric cancer is still a frequent cause of cancer related death. The 1st line 2 or 3 drugs regimen is still a debatable issue. HER2 targeted therapy has emerged as the standard of care, but it is unavailable in the Brazilian Public Health System. The end-point of this trial was overall survival (OS) in patients with metastatic gastric cancer treated in a public university hospital in Brazil. The secondary end-points were efficacy and safety of regimens with 2 (F+P) or 3 (EOX) drugs to develop an institutional guideline to facilitate optimal treatments. Materials and Methods: In this retrospective study, 1st line regimens were evaluated for OS and PFS stratified by age and ECOG using Cox regression. Results: 47 patients were treated over the last 3 years. In 1st line, 29 were treated with F+P (mean 59.3 years, 34.5% ECOG 2 and a mean of 5.69 cycles) and 16 with EOX (mean 47 years, 18.8% ECOG 2 and a mean of 5.44 cycles). The median OS was 13.8 months (95%CI 10.7-16.9). Response was evaluated in 40 cases and was 64.3% for EOX and 37.5% for F+P (p=0.25). The median PFS was 9.5 months for EOX and 5.6 months for F+P (HR 0.85, 95%CI 0.41-1.74). However, among patients with ECOG 2 mPFS was 3.70 vs 5.40 months, respectively (p=0.86). Regimens showed similar manageable adverse events. A total of 34 patients suffered progression and 14 received $2^{nd}$ line therapy. Diffuse histology (HR 1.89, 95%CI 1.22-2.88), achieving 2nd line (HR: 0.25, 95%CI 0.11-0.58) and treatment response (HR 0.23, 95%CI 0.12-0.47) were OS prognostic factors. Conclusions: Patients treated in our hospital had outcomes compatible with the literature. The regimen choice should be related to patient features. Second line treatment should be considered.

키워드

참고문헌

  1. Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97. https://doi.org/10.1016/S0140-6736(10)61121-X
  2. Basaran H, Koca T, Cerkesli AK, et al (2015). Treatment outcomes and survival study of gastric cancer patients: a retrospective analysis in an endemic region. Asian Pac J Cancer Prev, 16, 2055-60. https://doi.org/10.7314/APJCP.2015.16.5.2055
  3. Bilici A (2014). Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol, 20, 3905-15. https://doi.org/10.3748/wjg.v20.i14.3905
  4. Cunningham D, Starling N, Rao S, et al (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358, 36-46. https://doi.org/10.1056/NEJMoa073149
  5. Cutait R, Garicochea B, Cotti G (2001). Diagnostico e manejo do cancer gastrico familiar. Rev Col Bras Cir, 28, 5.
  6. Green S, Crowley J 1997. Clinical trials in oncology, London, Chapman & Hall.
  7. Guimbaud R, Louvet C, Ries P, et al (2014). Prospective, randomized, multicenter, phase iii study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a french intergroup (federation francophone de cancerologie digestive, federation nationale des centres de lutte contre le cancer, and groupe cooperateur multidisciplinaire en Oncologie) study. J Clin Oncol, 32, 3520-6. https://doi.org/10.1200/JCO.2013.54.1011
  8. Institute NC. 2009. Common terminology criteria for adverse events [Online]. [Accessed August 2014].
  9. Jatoi A, Foster N, Wieland B, et al (2006). The proteolysisinducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancer. Dis Esophagus, 19, 241-7. https://doi.org/10.1111/j.1442-2050.2006.00573.x
  10. Kang JH, Lee SI, Lim dH, et al (2012). Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol, 30, 1513-8. https://doi.org/10.1200/JCO.2011.39.4585
  11. Kang YK, Kang WK, Shin DB, et al (2009). Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol, 20, 666-73. https://doi.org/10.1093/annonc/mdn717
  12. Mantel N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, 163-70.
  13. Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5, 649-55. https://doi.org/10.1097/00000421-198212000-00014
  14. Park YH, Kim BS, Ryoo BY, et al (2006). A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer, 94, 959-63. https://doi.org/10.1038/sj.bjc.6603046
  15. Somi MH, Ghojazadeh M, Bagheri M, et al (2015). Clinicopathological factors and gastric cancer prognosis in the Iranian Population: a Meta-analysis. Asian Pac J Cancer Prev, 16, 853-7. https://doi.org/10.7314/APJCP.2015.16.3.853
  16. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. j natl cancer inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  17. Tong GX, Liang H, Chai J, et al (2014). Association of risk of gastric cancer and consumption of tobacco, alcohol and tea in the Chinese population. Asian Pac J Cancer Prev, 15, 8765-74. https://doi.org/10.7314/APJCP.2014.15.20.8765
  18. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7. https://doi.org/10.1200/JCO.2006.06.8429
  19. van Meerten E, Eskens FA, van Gameren EC, et al (2007). Firstline treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer, 96, 1348-52.
  20. Wagner AD, Unverzagt S, Grothe W, et al (2010). Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev, 4064.